PALATIN TECHNOLOGIES INC: Amendment to Restated Certificate of Incorporation to effect a 1-for-50 reverse stock split of common stock (effective 2025-08-08).
“On August 6, 2025, Palatin Technologies, Inc. (the “Company”) filed a certificate of amendment to the Company’s Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effectuate a 1-for-50 reverse stock split (the “Reverse Stock Split”) of the outstanding shares of the Company’s common stock (“Common Stock”).”
Listing & Compliance Notices
PALATIN TECHNOLOGIES INC received a nyse_american delisting notice notice regarding other (rules 1003(a), 1003(f)(v)).
“July 7, 2025, Palatin Technologies, Inc. (the “Company”) received written notification from NYSE American LLC (“NYSE American” or the “Exchange”) stating that a Listing Qualifications Panel (the “Panel”) of the Exchange’s Committee for Review (the “Committee for Review”) had unanimously determined to affirm the decision of the staff of NYSE American to initiate delisting proceedings of the Company’s common stock pursuant to Sections 1003(a) and 1003(f)(v) of the NYSE American Company Guide. A hearing on the proposed delisting was held before the Panel on June 18, 2025. The Company intends to”
Governance Changes
PALATIN TECHNOLOGIES INC: Filing of Certificate of Designation to create Series D Convertible Preferred Stock (effective 2025-06-10).
“On June 10, 2025, the Company filed a Certificate of Designation of the Rights, Powers, Preferences, Privileges, and Restrictions, of the Series D Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware to create the Preferred Stock.”
Listing & Compliance Notices
PALATIN TECHNOLOGIES INC received a nyse_american delisting notice notice regarding other (rules 1003(f)(v), 1009(a), 1003(a)(i), 1003(a)(ii), 1003(a)(iii)).
“May 7, 2025, the Company received notice from NYSE Regulation that it had suspended trading of the Company’s common stock on the NYSE American LLC stock exchange (“NYSE American”) and determined to commence proceedings to delist the Company’s common stock from the NYSE American as a result of its determination that the Company is no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the Company’s common stock. Trading of the Company’s common stock on the NYSE American was suspended on May 7, 2025 and began trading on th”
Listing & Compliance Notices
PALATIN TECHNOLOGIES INC received a nyse_american delisting notice notice regarding stockholders equity (rules 1009(a), 1003(a)(i), 1003(a)(ii), 1003(a)(iii)).
“April 10, 2025, Palatin Technologies, Inc. (the “Company”) received written notification from NYSE American LLC (“NYSE American” or the “Exchange”) stating that the NYSE Regulation has determined to commence proceedings to delist the Company’s common stock, par value $0.01 per share (the “Common Stock”) from NYSE American. NYSE Regulation has determined that the Company is no longer suitable for listing pursuant to Section 1009(a) of the NYSE American Company Guide (the “Company Guide”) as the Company was unable to demonstrate that it had regained compliance with Sections 1003(a)(i), (ii) and”
Earnings Releases
PALATIN TECHNOLOGIES INC reported financial results for fiscal third quarter ended March 31, 2024.
“On May 15, 2024, we issued a press release including results for our quarter ended March 31, 2024”
Earnings Releases
PALATIN TECHNOLOGIES INC reported the fiscal second quarter ended December 31, 2023 results: revenue $4.3 million.
“consists of gross product sales of Vyleesi, net of allowances and accruals. Vyleesi gross product sales to pharmacy distributors for the quarter ended December 31, 2023 were $4.3 million, with net product reven”
Material Agreements
PALATIN TECHNOLOGIES INC entered into Purchase Agreement with investors named on the signature page thereto (effective 2024-01-29).
“On January 29, 2024, Palatin Technologies, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the investors named on the signature page thereto, to sell in a registered direct offering (the “RD Offering”), an aggregate of 1,831,503 shares of common stock, $0.01 par value per share (the “Shares”), of the Company.”
M&A Transactions
PALATIN TECHNOLOGIES INC completed a disposition involving Cosette Pharmaceuticals, Inc. for up to $171 million, consisting of an upfront purchase price of $12 million plus contingent, sales-based milestone payments of up to $159 million (closed 2023-12-19).
“records pertaining to the historical sales and distribution of Vyleesi, as well as quality control and pharmacovigilance records and other records. Palatin will receive up to $171 million, consisting of an upfront purchase price of $12 million plus contingent, sales-based milestone payments of up to $159 million. The closing of the transaction took place”
Material Agreements
PALATIN TECHNOLOGIES INC entered into Asset Purchase Agreement with Cosette Pharmaceuticals, Inc. valued at up to $171 million, consisting of an upfront purchase price of $12 million plus contingent, sales-ba (effective 2023-12-19).
“On December 19, 2023, Palatin Technologies, Inc. (“Palatin”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Cosette Pharmaceuticals, Inc. (“Cosette”) pursuant to which Cosette acquired from Palatin worldwide rights to Vyleesi®.”
Listing & Compliance Notices
PALATIN TECHNOLOGIES INC received a nyse_american extension granted notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii)).
“December 13, 2023, Palatin Technologies, Inc. (the “Company”) received notification (the “Plan Letter”) that the NYSE American (the “Exchange”) has accepted the Company’s plan to regain compliance (the “Plan”) with the Exchange's continued listing standards regarding stockholders' equity, as set forth in Sections 1003(a)(i) and (ii) of the NYSE American Company Guide. As previously reported, on October 10, 2023, the Company received notification (the "Deficiency Letter") from the NYSE American that it was not in compliance with the continued listing standards set forth in the NYSE American Com”
Listing & Compliance Notices
PALATIN TECHNOLOGIES INC received a nyse_american noncompliance notice notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii)).
“October 10, 2023, the Company received notification (the "Deficiency Letter") from the NYSE American that it was not in compliance with the continued listing standards set forth in the NYSE American Company Guide (the "Company Guide"). Specifically, the Deficiency Letter indicated that the Company was not in compliance with Sections 1003(a)(i) and 1003(a)(ii) of the Company Guide, requiring a listed company to have stockholders' equity of (i) at least $2.0 million if it has reported losses from continuing operations or net losses in two of its three most recent fiscal years and (ii) at least $”
Earnings Releases
PALATIN TECHNOLOGIES INC reported financial results for fiscal first quarter ended September 30, 2023.
“On November 14, 2023, we issued a press release including results for our quarter ended September 30, 2023, and announcing a teleconference and webcast to be held November 14, 2023, at 11:00 a.m. Eastern time, which will include a discussion on results of operations in greater detail and an update on corporate developments.”
Material Agreements
PALATIN TECHNOLOGIES INC entered into Purchase Agreement with the investor named on the signature page thereto valued at $4.5 million net proceeds (effective 2023-10-20).
“On October 20, 2023, Palatin Technologies, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the investor named on the signature page thereto, to sell in a registered direct offering”
Earnings Releases
PALATIN TECHNOLOGIES INC reported first quarter of fiscal year 2024 ended September 30, 2023 results: revenue $4.6 million in gross product revenue; $2.1 million in net product revenue.
“Preliminary Quarter Ended September 30, 2023 Vyleesi ® Product Revenue Results · 7 Consecutive Quarters of Double-Digit Growth in Product Revenue and Prescriptions Dispensed · $4.6 million in Gross Product Revenue o 11% growth over prior quarter; 100% growth over comparable quarter last year · $2.1 million in Net Product Revenue o 18% growth over prior quarter;”
Listing & Compliance Notices
PALATIN TECHNOLOGIES INC received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii), 1009, 1010).
“October 10, 2023, Palatin Technologies, Inc. (the “Company”) received a letter (the “Letter”) from the staff of NYSE American LLC (the “Exchange”) stating that the Company’s stockholders’ equity as reported in its Annual Report on Form 10-K for the year ended June 30, 2023 (“Form 10-K”) was not in compliance with the Exchange’s continued listing standards under Section 1003(a)(i) and (ii) of the NYSE American Company Guide (the “Company Guide”). Section 1003(a)(i) requires a listed company to have stockholders’ equity $2 million or more if the listed company has reported losses from continuing”
Earnings Releases
PALATIN TECHNOLOGIES INC reported financial results for fiscal fourth quarter ended June 30, 2023.
“Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal fourth quarter and fiscal year ended June 30, 2023.”
Earnings Releases
PALATIN TECHNOLOGIES INC reported financial results for fiscal year ended June 30, 2023.
“On September 28, 2023, we issued a press release including results for our fiscal year ended June 30, 2023 and announcing a teleconference and webcast to be held September 28, 2023, at 11:00 a.m. Eastern time, which will include a discussion on results of operations in greater detail and an update on corporate developments.”
Shareholder Votes
PALATIN TECHNOLOGIES INC shareholders approved Advisory Vote on Compensation of Named Executive Officers for fiscal year ended June 30, 2022 at the 2023-06-20 meeting.
“The stockholders voted to advise the Company that they do approve the compensation of the Company’s named executive officers, by the votes set forth below: For Against Abstain 1,332,202 634,396 18,140 Broker Non-Votes: 2,999,632”
Shareholder Votes
PALATIN TECHNOLOGIES INC shareholders approved Approval of an Amendment to the Company's 2011 Stock Incentive Plan to Increase the Number of Shares Available for Equity Awards by 1,000,000 Shares at the 2023-06-20 meeting.
“The stockholders approved the amendment to the Company’s 2011 Stock Incentive Plan to increase the number of shares available for equity awards by 1,000,000 shares, by the votes set forth below: For Against Abstain 1,312,262 634,396 18,140 Broker Non-Votes: 2,999,632”
Shareholder Votes
PALATIN TECHNOLOGIES INC shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-20 meeting.
“The stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2023, by the votes set forth below: For Against Abstain 4,575,827 378,813 29,730 Broker Non-Votes: Not Applicable”
Shareholder Votes
PALATIN TECHNOLOGIES INC shareholders approved Election of Directors at the 2023-06-20 meeting.
“The stockholders elected the following seven directors to serve until the next annual meeting, or until their successors are elected and qualified, by the votes set forth below: Nominee FOR WITHHELD 01) Carl Spana, Ph.D. 1,525,651 459,087 02) John K.A. Prendergast, Ph.D. 1,275,879 708,859 03) Robert K. deVeer, Jr. 1,546,992 437,746 04) J. Stanley Hull 1,553,842 430,896 05) Alan W. Dunton, M.D. 1,562,480 422,258 06) Arlene M. Morris 1,384,972 599,766 07) Anthony M. Manning, Ph.D. 1,542,279 442,459 Broker Non-Votes: 2,999,632 for each director”
Earnings Releases
PALATIN TECHNOLOGIES INC reported fiscal third quarter ended March 31, 2023 results: revenue net product revenue of $1.2 million.
“For the fiscal third quarter ended March 31, 2023: – Gross product sales were $3.4 million, an increase of 31% over the prior quarter, and an increase of 165% over the comparable quarter last year. – Net product revenue of $1.2 million increased 16% over the prior quarter and increased 453% over the comparable quarter last year.”
Material Agreements
PALATIN TECHNOLOGIES INC entered into Equity Distribution Agreement with Canaccord Genuity LLC valued at up to approximately $50 million (effective 2023-04-12).
“On April 12, 2023, Palatin Technologies, Inc. (the “ Company ”) entered into a new Equity Distribution Agreement, dated April 12, 2023 (the “ Equity Distribution Agreement ”), with Canaccord Genuity LLC (“ Canaccord ”), pursuant to which the Company may, from time to time, offer and sell, through Canaccord, shares of the Company’s common stock, par value $0.01 per share (the “ Shares ”), having an aggregate offering price of up to approximately $50 million.”
Earnings Releases
PALATIN TECHNOLOGIES INC reported fiscal second quarter ended December 31, 2022 results: revenue $1 million.
“value metrics, notably net product sales increased 18% and prescriptions dispensed increased 12% over the prior quarter. We are excited that net product revenue of approximately $1 million for the quarter ended December 31, 2022, exceeded Vyleesi operating expenses.” Business Highlights and Recent Updates · Anti-Inflammatory / Autoimmune Programs o PL9643”
Earnings Releases
PALATIN TECHNOLOGIES INC reported fiscal first quarter ended September 30, 2022 results: revenue $2.3 million, net income $8.3 million, EPS $(0.86) per common share.
“as of June 30, 2022. · Vyleesi® (bremelanotide injection) for the treatment of Hypoactive Sexual Desire Disorder (HSDD): Gross product sales to pharmacy distributors amounted to $2.3 million, while net product revenue increased 13% and prescriptions dispensed increased 17%, over the prior quarter. 1 Business Highlights and Recent Updates · Anti-Inflammatory /”
Material Agreements
PALATIN TECHNOLOGIES INC entered into Purchase Agreement with a certain institutional investor valued at approximately $9.1 million (effective 2022-10-31).
“On October 31, 2022, Palatin Technologies, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a certain institutional investor to sell, in a registered direct offering (the “Offering”), an aggregate of up to (i) 1,020,000 shares of common stock, $0.01 par value per share, of the Company, (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 798,182 shares of the Company’s common stock, and (iii) common warrants (the “Common Warrants”) to purchase up to 1,818,182 shares of the Company’s common stock.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.